Why new cancer drugs are such a disappointment

UK study prompts calls to raise regulation standards
thumbs down

The majority of new cancer drugs appear to be no better than their predecessors, research suggests.

Most have entered the market without clear evidence that they improve patient survival or quality of life, according to UK policy experts.

Even where drugs did show survival gains over existing treatments, these were often marginal, their results show.